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The	 long-	term	 safety	 and	 efficacy	 of	 rFIXFc	 prophylaxis	was	 confirmed	 in	 the	 B-	
YOND	study	(NCT01425723),	an	extension	of	the	B-	LONG	clinical	trial.
Objective:	The	aim	of	this	post-	hoc	analysis	was	to	evaluate	the	efficacy	of	a	≥14-	day	
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reducing	 the	 frequency	 of	 bleeding	 episodes,	 and	 improving	 joint	
outcomes	and	quality	of	life.1,2	For	prophylaxis	in	hemophilia	B,	the	
use	 of	 conventional	 half-	life	 factor	 IX	 (FIX)	 products	 requires	 fre-















rFIXFc	 is	 associated	with	 low	 annualized	 bleeding	 rates	 (ABRs)	 in	
male	patients	aged	≥12	years	with	severe	hemophilia	B.6	The	exten-
sion	 study,	B-	YOND,	has	 confirmed	 the	 long-	term	safety	and	effi-
cacy	of	prophylaxis	with	rFIXFc7;	key	results	upon	completion	of	the	
B-	YOND	study	are	expected	in	2018.
The	 approved	 indication	 for	 rFIXFc	 in	 the	EU	was	 updated	 in	
July	2017	to	include	a	dosing	interval	of	≥14	days	for	use	in	patients	
with	 hemophilia	 B	 who	 are	 well	 controlled	 with	 rFIXFc	 adminis-




B-	LONG	 (NCT01027364)	 was	 a	 phase	 3,	 non-	randomized,	 open-	
label,	 multicenter	 study,	 with	 primary	 and	 secondary	 endpoints	






rFIXFc	 100	IU/kg	 at	 an	 interval	 of	 every	 10	days,	 with	 the	 interval	
adjusted	as	needed	based	on	pharmacokinetics	(PK)	and/or	outcome	














There	were	 four	 treatment	 groups	 in	 B-	YOND:	 Group	 1	 received	
prophylaxis	with	rFIXFc	20-	100	IU/kg	every	7	days	(weekly	prophylaxis);	
Group	 2	 received	 interval-	adjusted	 prophylaxis	with	 rFIXFc	 100	IU/kg	













3  | RESULTS AND DISCUSSION
Twenty-	two	patients	 received	 rFIXFc	 prophylaxis	with	 a	 dos-
ing	 interval	 of	 ≥14	days	 at	 any	 time	 during	 B-	LONG	 or	 B-	
YOND,	until	 the	 time	of	 the	 second	 interim	B-	YOND	analysis	
(September	2015).	The	median	age	at	baseline	was	34.5	years	
with	 the	 vast	 majority	 of	 patients	 having	 <1%	 endogenous	
FIX	 activity.	 The	 median	 terminal	 half-	life	 (t½)	 of	 rFIXFc	 was	
99.8	hours	(Table	1).
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prior	 to	 the	 extension	 (Figure	1).	 The	 median	 (IQR)	 rFIXFc	 ex-
posure	 duration	 before	 extending	 the	 dosing	 interval	 was	 116	
(61-	205)	days,	 the	 median	 (IQR)	 weekly	 consumption	 was	 63	







trough	 level	 while	 on	 ≥14-	day	 dosing	was	 estimated	 to	 be	 2.80	
(2.3-	3.8)	IU/dL	based	on	149	measurements.













Subjects aged ≥12 years with a dosing interval of ≥14
days at any time during this period (N = 22)
At the time of extending the dosing interval:
18 patients were treated with individualized prophylaxis
1 patient was on once-weekly prophylaxis
2 patients were treated on demand
1 patient started B-LONG on a 14-day interval
Phase 3 study Phase 3 extension study












Group 3: On-demand treatment
Group 4: On-demand treatment
Group 2: Interval-adjusted prophylaxis
Group 1: Dose-adjusted weekly prophylaxis
Group 3: Modified prophylaxis
Group 2: Interval-adjusted prophylaxis




Median (IQR) or n (%)
Patients treated with ≥14- day 



































IQR,	 interquartile	 range;	 rFIXFc,	 recombinant	 factor	 IX	 Fc	 fusion	
protein.
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interval	of	≥14	days	at	the	time	of	the	second	interim	data	cut,	al-
though	three	of	these	17	patients	had	had	a	temporary	reduction	
(50,	 30,	 and	22	days)	 in	 the	dosing	 interval	 to	<14	days	 at	 some	









interval-	adjusted	 prophylaxis	 in	 B-	LONG,6	 2.25	 (0.87-	4.47)	 with	
interval-	adjusted	 prophylaxis	 and	 2.42	 (1.26-	5.40)	 with	 modified	
prophylaxis	the	interim	analysis	of	B-	YOND.7
The	 median	 (IQR)	 spontaneous	 ABR	 during	 the	 period	 with	 a	
≥14-	day	 dosing	 interval	was	 0.7	 (0.3-	1.1)	 (Table	3).	 This	 compares	
with	a	median	(IQR)	spontaneous	ABR	of	0.9	(0.0-	2.3)	with	interval-	







and	57	days)	 to	 obtain	 robust	 estimates	of	ABR	 and	 an	 additional	
two	patients	because	they	had	received	on-	demand	treatment	be-
fore	the	dosing	interval	was	changed	to	≥14	days.











In	 conclusion,	 these	data	 confirm	 that	 patients	who	were	well	
controlled	 on	 a	 10-	day	 dosing	 interval	 of	 rFIXFc	 prophylaxis	 re-




FIX	products,	and	 further	 reduces	 the	burden	 for	patients,	poten-
tially	positively	impacting	adherence.
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≥14- day dosing 







ing	 the	 dosing	 interval	 to	 ≥14	day	 (ie,	 the	 two	 patients	 receiving	 on-	
demand	 treatment	 were	 excluded),	 and	 who	 had	 been	 observed	 for	
≥6	mo	(thereby	excluding	an	additional	two	patients).	
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